GLP-1 Drug Concerns, Zepbound for Sleep Apnea, and Heatwave Safety

In this episode, Dr. Chi-Ming Chow delves into GLP-1 drugs and their potential link to eating disorders, examining study findings and concerns. He discusses challenges with compounded GLP-1 receptor agonists, study limitations, and the need for further research. The episode also covers Health Canada's approval of Zepbound for severe sleep apnea, including its mechanism and clinical trial outcomes. Dr. Chow reviews side effects of GLP-1 drugs like tirzepatide and offers tips for keeping children safe during heatwaves, focusing on air conditioning, car safety, and gender-specific effects. The episode wraps up with strategies for managing women's heat exposure. (0:00) Introduction and overview (0:31) GLP-1 drug use and eating disorders: study findings and concerns (2:19) Challenges with compounded GLP-1 receptor agonists (2:44) Prevalence of GLP-1 drug use by eating disorder subtype (3:08) Study limitations and need for future research (3:38) Health Canada approval of Zepbound for severe sleep apnea (4:12) Zepbound's mechanism, comparison, and administration guidelines (5:15) Clinical trial results and impact on sleep apnea severity (6:08) Side effects of GLP-1 drugs like tirzepatide (7:00) Keeping children safe during a heatwave: strategies and signs of illness (8:51) Role of air conditioning and car safety for children (9:41) Gender-specific effects of hot weather (10:03) Biological and hormonal factors in women's heat susceptibility (11:22) Societal, occupational, and public health strategies for women's heat exposure (12:05) Closing remarks and episode summary